10.1016/j.metabol.2011.01.010 57
Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, et al
In one of the four SCLC tumour tissues (25%) screened, preferential c-MET overexpression and activation of p-MET (both the phosphoepitopes pY1003 and pY1230/1234/1235) along the tumour expanding invasive front were identified (Figures 5A and B)
What ProHealth States: According to the company's product page, BPC-157 is marketed for support of tissue pathways, cellular processes, and biological functions based on preclinical research findings
Direct pharmacy routes can sometimes offer more transparency and quality assurance but may require more coordination on the user's part
"As we move into the second half of 2025, our focus is on investing in capabilities that will deepen the value customers can access on our platform